JP7742892B2 - 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法 - Google Patents

抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法

Info

Publication number
JP7742892B2
JP7742892B2 JP2023565355A JP2023565355A JP7742892B2 JP 7742892 B2 JP7742892 B2 JP 7742892B2 JP 2023565355 A JP2023565355 A JP 2023565355A JP 2023565355 A JP2023565355 A JP 2023565355A JP 7742892 B2 JP7742892 B2 JP 7742892B2
Authority
JP
Japan
Prior art keywords
seq
chain variable
amino acid
region
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023565355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516631A (ja
Inventor
バイテン・ジャオ
レイ・ワン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Publication of JP2024516631A publication Critical patent/JP2024516631A/ja
Priority to JP2025148773A priority Critical patent/JP2025183307A/ja
Application granted granted Critical
Publication of JP7742892B2 publication Critical patent/JP7742892B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023565355A 2021-04-23 2022-04-22 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法 Active JP7742892B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025148773A JP2025183307A (ja) 2021-04-23 2025-09-09 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/089164 2021-04-23
CN2021089164 2021-04-23
PCT/US2022/025966 WO2022226317A1 (en) 2021-04-23 2022-04-22 Anti-cd70 antibodies, conjugates thereof and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025148773A Division JP2025183307A (ja) 2021-04-23 2025-09-09 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法

Publications (2)

Publication Number Publication Date
JP2024516631A JP2024516631A (ja) 2024-04-16
JP7742892B2 true JP7742892B2 (ja) 2025-09-22

Family

ID=81597869

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023565355A Active JP7742892B2 (ja) 2021-04-23 2022-04-22 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法
JP2025148773A Pending JP2025183307A (ja) 2021-04-23 2025-09-09 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025148773A Pending JP2025183307A (ja) 2021-04-23 2025-09-09 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法

Country Status (8)

Country Link
US (1) US20250066490A1 (enExample)
EP (1) EP4326768A1 (enExample)
JP (2) JP7742892B2 (enExample)
CN (1) CN117203238A (enExample)
AU (1) AU2022262644B2 (enExample)
CA (1) CA3216459A1 (enExample)
TW (1) TW202308699A (enExample)
WO (1) WO2022226317A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
KR20250093370A (ko) * 2022-10-26 2025-06-24 젠맵 에이/에스 Cd70 항체 약물 접합체 및 그의 사용 방법
TWI871168B (zh) * 2023-01-16 2025-01-21 大陸商上海華奧泰生物藥業股份有限公司 靶向cd70的抗體或結合cd70的抗原結合片段及其製備方法和應用
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006518753A (ja) 2003-02-20 2006-08-17 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
JP2009509510A (ja) 2005-09-26 2009-03-12 メダレックス インコーポレーティッド Ｃｄ７０に対するヒトモノクローナル抗体
JP2010513306A (ja) 2006-12-14 2010-04-30 メダレックス インコーポレーティッド Ｃｄ７０に結合するヒト抗体およびその使用
JP2015501134A (ja) 2011-09-22 2015-01-15 アムジエン・インコーポレーテツド Ｃｄ２７ｌ抗原結合タンパク質

Family Cites Families (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
KR960029336A (ko) 1995-01-09 1996-08-17 김충환 캄토테신 유도체, 그의 제조 방법 및 이를 함유하는 항암제
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
EP0871490B1 (en) 1995-12-22 2003-03-19 Bristol-Myers Squibb Company Branched hydrazone linkers
DK0825186T3 (da) 1996-08-16 2002-07-22 Pfizer 2-aminobenzazepinderivater og deres anvendelse til behandling af immunosuppression
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US5985837A (en) 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6512162B2 (en) 1998-07-10 2003-01-28 Calgene Llc Expression of eukaryotic peptides in plant plastids
US20030167531A1 (en) 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
CA2388432A1 (en) 1999-10-21 2001-04-26 Monsanto Company Post-translational modification of recombinant proteins produced in plants
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7591944B2 (en) 2002-01-23 2009-09-22 Johnson Matthey Plc Sulphided ion exchange resins
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
CA2508831C (en) 2002-12-13 2012-05-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
US20080025989A1 (en) * 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
DK1691833T3 (da) 2003-11-28 2010-05-03 Micromet Ag Præparater der omfatter polypeptider
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
WO2006044643A2 (en) 2004-10-15 2006-04-27 Seattle Genetics, Inc. Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
PL2099823T5 (pl) 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
CN101605906A (zh) * 2006-12-14 2009-12-16 梅达雷克斯公司 结合cd70的人类抗体及其用途
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
EP2170888B1 (en) 2007-06-29 2015-04-22 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2009117531A1 (en) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
CA2732437C (en) 2008-08-01 2017-11-21 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
WO2010081004A1 (en) 2009-01-09 2010-07-15 Seattle Genetics, Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
PL3912643T3 (pl) 2009-02-13 2023-01-23 Immunomedics Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
JP5784592B2 (ja) 2009-06-03 2015-09-24 イミュノジェン・インコーポレーテッド 抱合方法
CN105669553A (zh) 2009-08-18 2016-06-15 文蒂雷克斯药品公司 作为toll样受体调节剂的取代的苯并氮杂*
CN105669552A (zh) 2009-08-18 2016-06-15 文蒂雷克斯药品公司 作为toll样受体调节剂的取代的苯并氮杂*
BR112012009329A2 (pt) 2009-10-22 2016-06-07 Gilead Sciences Inc derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia)
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN103200950B (zh) 2010-06-10 2016-03-16 西雅图基因公司 新颖的耳他汀衍生物及其用途
ES2874306T3 (es) 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
US20120082658A1 (en) 2010-10-01 2012-04-05 Ventirx Pharmaceuticals, Inc. Methods for the Treatment of Allergic Diseases
KR101866893B1 (ko) 2010-10-01 2018-06-14 벤티알엑스 파마슈티칼스 인코포레이티드 Tlr 아고니스트의 치료적 용도 및 병용 요법
DK2663555T3 (en) 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
MX346387B (es) 2011-01-12 2017-03-02 Ventirx Pharmaceuticals Inc Benzoazepinas sustituidas como moduladores de receptores tipo toll.
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
ES2691745T3 (es) 2011-04-08 2018-11-28 Janssen Sciences Ireland Uc Derivados de pirimidina para el tratamiento de infecciones víricas
PL2709989T3 (pl) 2011-05-18 2018-06-29 Janssen Sciences Ireland Uc Pochodne chinazoliny do leczenia infekcji wirusowych i dalszych chorób
EP2717916B1 (en) 2011-06-10 2017-03-08 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CN107043339B (zh) 2011-07-19 2019-09-06 希默赛生物技术有限责任公司 新交联试剂、大分子、治疗用偶联物及其合成方法
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
EP2794565B1 (en) 2011-12-21 2017-07-26 Novira Therapeutics Inc. Hepatitis b antiviral agents
EA039373B1 (ru) 2012-02-08 2022-01-19 Янссен Сайенсиз Айрлэнд Юси Производные пиперидино-пиримидина для лечения вирусных инфекций
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
JP6302906B2 (ja) 2012-08-10 2018-03-28 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染および他の疾患を治療するためのアルキルピリミジン誘導体
MX386924B (es) 2012-10-10 2025-03-19 Janssen Sciences Ireland Uc Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades.
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
HRP20180268T4 (hr) 2012-10-23 2026-03-27 Synaffix B.V. Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
US9663474B2 (en) 2012-11-16 2017-05-30 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections
KR102300861B1 (ko) 2013-02-21 2021-09-10 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
ES2836881T3 (es) 2013-07-30 2021-06-28 Janssen Sciences Ireland Unlimited Co Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales
TWI526446B (zh) 2013-09-27 2016-03-21 中國醫藥大學附設醫院 喜樹鹼的新穎２０（ｓ）－磺基脒衍生物及其抗腫瘤劑的用途
WO2015057066A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
CN105813653B (zh) 2013-12-19 2020-06-26 西雅图基因公司 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
EP3107557B1 (en) 2014-02-17 2021-06-09 Seagen Inc. Hydrophilic antibody-drug conjugates
ES2804101T3 (es) 2014-04-22 2021-02-03 Hoffmann La Roche Compuestos de 4-amino-imidazoquinolina
US9884817B2 (en) 2014-06-13 2018-02-06 Novartis Ag Auristatin derivatives and conjugates thereof
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
EP3177633B1 (en) 2014-08-04 2022-07-20 SynAffix B.V. Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
HRP20241124T1 (hr) 2014-09-11 2024-11-22 Seagen Inc. Ciljana isporuka lijekovitih tvari koje sadrže tercijarni amin
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
HUE053704T2 (hu) 2014-12-08 2021-07-28 Hoffmann La Roche 3-szubsztitutált 5-amino-6H-tiazolo[4,5-d]pirimidin-2,7-dion vegyületek vírusfertõzések kezelésére és megelõzésére
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
SG11201606876RA (en) 2015-03-04 2016-10-28 Gilead Sciences Inc Toll like receptor modulator compounds
HUE042563T2 (hu) 2015-03-06 2019-07-29 Hoffmann La Roche Benzazepin-dikarboxamid vegyületek
AU2016232705C1 (en) 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
WO2017046112A1 (en) 2015-09-17 2017-03-23 F. Hoffmann-La Roche Ag Sulfinylphenyl or sulfonimidoylphenyl benzazepines
JP7232047B2 (ja) 2015-10-27 2023-03-02 コーニンクレッカ フィリップス エヌ ヴェ アンチ・ファウリング・システム、並びに、アンチ・ファウリング・システムを制御するコントローラー及び方法
MX383893B (es) 2015-11-02 2025-03-14 Ventirx Pharmaceuticals Inc Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar el cáncer.
US10393904B2 (en) 2015-11-06 2019-08-27 Weatherford Technology Holdings, Llc Predicting stress-induced anisotropy effect on acoustic tool response
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
EP3419670A2 (en) 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
PL3430397T3 (pl) 2016-03-14 2022-04-04 Biogen International Neuroscience Gmbh Oznaczenie fagocytozy zależnej od przeciwciał do wiarygodnych pomiarów wychwytu zagregowanych białek
RS63116B1 (sr) 2016-05-06 2022-05-31 Shanghai De Novo Pharmatech Co Ltd Derivat benzazepina, postupak za dobijanje, farmaceutska kompozicija i njegova upotreba
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
WO2017202704A1 (en) 2016-05-23 2017-11-30 F. Hoffmann-La Roche Ag Benzazepine dicarboxamide compounds with tertiary amide function
EP3464274B1 (en) 2016-05-23 2020-05-27 H. Hoffnabb-La Roche Ag Benzazepine dicarboxamide compounds with secondary amide function
EP3468963B1 (en) 2016-06-12 2021-10-27 F. Hoffmann-La Roche AG Dihydropyrimidinyl benzazepine carboxamide compounds
KR20240010534A (ko) 2016-08-09 2024-01-23 씨젠 인크. 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
AU2018236272B2 (en) 2017-03-15 2022-03-31 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
US20200199247A1 (en) 2017-06-07 2020-06-25 Silverback Therapeutics, Inc. Antibody conjugates of immune-modulatory compounds and uses thereof
EP3665195A4 (en) 2017-08-11 2021-05-19 Research Development Foundation MANIPULATED ANTIBODY FC VARIANTS FOR INCREASED SERUM HALF-VALUE
CN119219654A (zh) 2017-12-15 2024-12-31 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
CN119792569A (zh) 2018-01-10 2025-04-11 财团法人生物技术开发中心 抗体protac偶联物
MX2020008267A (es) 2018-02-20 2020-09-21 Seattle Genetics Inc Compuestos de auristatina f hidrofoba y conjugados de los mismos.
WO2019213046A1 (en) 2018-05-01 2019-11-07 Cellmosaic Inc. Branched sugar alcohol-based compounds, and compositions and methods thereof
EP3849971A2 (en) 2018-09-12 2021-07-21 Silverback Therapeutics, Inc. Substituted benzazepine compounds, conjugates, and uses thereof
WO2020056194A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
JP2021535930A (ja) 2018-09-17 2021-12-23 キュラティス インコーポレイティッド Ｓｔｉｎｇアゴニストを含む抗原性補強剤及びワクチン組成物
TW202446772A (zh) 2018-10-11 2024-12-01 日商小野藥品工業股份有限公司 Ｓｔｉｎｇ促效化合物
EP3868773A4 (en) 2018-10-12 2022-07-13 Shanghai Jemincare Pharmaceuticals Co., Ltd. CYCLIC DINUCLEOTIDE COMPOUND AND ITS APPLICATIONS
WO2020123425A2 (en) 2018-12-12 2020-06-18 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
US10781239B2 (en) 2018-12-28 2020-09-22 Vividion Therapeutics, Inc. In vivo engineered cereblon protein
CN118652275A (zh) 2019-01-30 2024-09-17 四川科伦博泰生物医药股份有限公司 喜树碱衍生物及其水溶性前药、包含其的药物组合物及其制备方法和用途
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
EP3976112A1 (en) 2019-06-03 2022-04-06 Synaffix B.V. Acetal-based cleavable linkers
CN116120451A (zh) * 2021-06-17 2023-05-16 南京蓝盾生物科技有限公司 抗cd70内化的抗体、抗体偶联物及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006518753A (ja) 2003-02-20 2006-08-17 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
JP2009509510A (ja) 2005-09-26 2009-03-12 メダレックス インコーポレーティッド Ｃｄ７０に対するヒトモノクローナル抗体
JP2010513306A (ja) 2006-12-14 2010-04-30 メダレックス インコーポレーティッド Ｃｄ７０に結合するヒト抗体およびその使用
JP2015501134A (ja) 2011-09-22 2015-01-15 アムジエン・インコーポレーテツド Ｃｄ２７ｌ抗原結合タンパク質

Also Published As

Publication number Publication date
CA3216459A1 (en) 2022-10-27
CN117203238A (zh) 2023-12-08
EP4326768A1 (en) 2024-02-28
AU2022262644B2 (en) 2026-05-21
AU2022262644A9 (en) 2023-11-16
WO2022226317A1 (en) 2022-10-27
JP2025183307A (ja) 2025-12-16
US20250066490A1 (en) 2025-02-27
TW202308699A (zh) 2023-03-01
AU2022262644A1 (en) 2023-11-09
JP2024516631A (ja) 2024-04-16

Similar Documents

Publication Publication Date Title
AU2022262644B2 (en) Anti-cd70 antibodies, conjugates thereof and methods of using the same
JP7756194B2 (ja) Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）結合タンパク質
JP7717832B2 (ja) Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法
US20250381289A1 (en) Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
KR20250130409A (ko) 링커, 약물 링커 및 그의 접합체 및 그의 사용 방법
EP4228705A1 (en) Anti-msln binding agents, conjugates thereof and methods of using the same
US20250213715A1 (en) Anti-cspg4 binding agents, conjugates thereof and methods of using the same
US20250090680A1 (en) Gpc3 binding agents, conjugates thereof and methods of using the same
HK40104647A (en) Cd70 binding agents, conjugates thereof and methods of use thereof
HK40105064A (en) Folr1 binding agents, conjugates thereof and methods of using the same
CN118591392A (zh) Gpc3结合剂、其缀合物以及使用它们的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250207

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250530

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250812

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250909

R150 Certificate of patent or registration of utility model

Ref document number: 7742892

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150